What Are the Fundamentals of DaVita (DVA)?

By Ken Smith • Monday, August 07 12:23 • Permanent Link

We're taking a closer look at DaVita today, as the chatter surrounding the stock has increased notably in the last few weeks. Today, its shares moved 4.9% compared to 1.0% for the S&P 500. Increased investor interest and volatility surrounding the stock are not reason enough to buy in -- you should first perform your own due diligence. Here are some figures that can get you started:

DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States.
DaVita has moved 29.0% over the last year compared to 10.0% for the S&P 500 -- a difference of 19.0%
DVA has an average analyst rating of hold and is 9.33% away from its mean target price of $104.43 per share
Its trailing 12 month earnings per share (EPS) is $5.32
DaVita has a trailing 12 month Price to Earnings (P/E) ratio of 21.5
Its forward earnings per share (EPS) is $7.22 and its forward P/E ratio is 15.8
DVA has a Price to Earnings Growth (PEG) ratio of 1.32, which shows the company is fairly valued compared to its earnings.
The company has a Price to Book (P/B) ratio of 10.24
DaVita is part of the Health Care sector

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.